New PI/II CT for overexpressing cancers

Published: 26-Nov-2003

Medarex announces phase I/II clinical trial development of MDX-214 for the treatment of EGF-R overexpressing cancers


Medarex announces phase I/II clinical trial development of MDX-214 for the treatment of EGF-R overexpressing cancers

An Investigational New Drug (IND) application has been filed by Medarex with the FDA to initiate Phase I/II clinical trials of MDX-214 to treat patients with cancers that overexpress the epidermal growth factor receptor, or EGFr. MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. An open-label, dose- escalation Phase I/II study is expected to accrue up to 48 patients with refractory or relapsed EGFr-expressing cancers, including cancers of the head and neck, breast, colon, prostate, lung and ovary.

'We believe that MDX-214 is an innovative approach for the potential treatment of EGFr-expressing cancers,' said Donald L. Drakeman, president and ceo of Medarex. 'MDX-214 is designed to not only disrupt the EGFr signaling pathway and inhibit tumor cell growth but also to recruit killer immune cells to the tumor site.'

You may also like